[1]
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England journal of medicine. 2001 May 10:344(19):1434-41
[PubMed PMID: 11346808]
[2]
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet (London, England). 2018 Jan 20:391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9
[PubMed PMID: 29129436]
Level 1 (high-level) evidence
[3]
Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. The Journal of clinical endocrinology and metabolism. 2000 Sep:85(9):3069-76
[PubMed PMID: 10999788]
[4]
Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2003 Jan:18(1):9-17
[PubMed PMID: 12510800]
[5]
Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. The Journal of clinical endocrinology and metabolism. 2002 Oct:87(10):4528-35
[PubMed PMID: 12364430]
Level 1 (high-level) evidence
[6]
Liu CL, Lee HC, Chen CC, Cho DY. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clinical and investigative medicine. Medecine clinique et experimentale. 2017 Jun 26:40(3):E146-E157. doi: 10.25011/cim.v40i3.28394. Epub 2017 Jun 26
[PubMed PMID: 28653616]
Level 1 (high-level) evidence
[7]
Wang YK, Qin SQ, Ma T, Song W, Jiang RQ, Guo JB, Li K, Zhang YM. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. Medicine. 2017 May:96(21):e6970. doi: 10.1097/MD.0000000000006970. Epub
[PubMed PMID: 28538396]
Level 2 (mid-level) evidence
[8]
Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs. 2008:68(18):2709-37. doi: 10.2165/0003495-200868180-00012. Epub
[PubMed PMID: 19093708]
[9]
Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. The New England journal of medicine. 2007 Nov 15:357(20):2028-39
[PubMed PMID: 18003959]
[10]
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis and rheumatism. 2009 Nov:60(11):3346-55. doi: 10.1002/art.24879. Epub
[PubMed PMID: 19877063]
Level 1 (high-level) evidence
[11]
ACOG Committee on Clinical Practice Guidelines–Gynecology. Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2. Obstetrics and gynecology. 2022 Apr 1:139(4):698-717. doi: 10.1097/AOG.0000000000004730. Epub
[PubMed PMID: 35594133]
Level 1 (high-level) evidence
[12]
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis care & research. 2017 Aug:69(8):1095-1110. doi: 10.1002/acr.23279. Epub 2017 Jun 6
[PubMed PMID: 28585410]
[13]
Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Clinical Guidelines Committee of the American College of Physicians, Cross JT Jr, Fitterman N, Lin JS, Maroto M, Obley AJ, Tice JA, Tufte JE. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Annals of internal medicine. 2023 Feb:176(2):224-238. doi: 10.7326/M22-1034. Epub 2023 Jan 3
[PubMed PMID: 36592456]
[14]
Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine reviews. 2005 Aug:26(5):688-703
[PubMed PMID: 15769903]
[15]
Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004 Aug:35(2):375-82
[PubMed PMID: 15268886]
Level 1 (high-level) evidence
[16]
Cheng ML, Gupta V. Teriparatide - Indications beyond osteoporosis. Indian journal of endocrinology and metabolism. 2012 May:16(3):343-8. doi: 10.4103/2230-8210.95661. Epub
[PubMed PMID: 22629497]
[17]
Canalis E. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis. European journal of endocrinology. 2018 Feb:178(2):R33-R44. doi: 10.1530/EJE-17-0920. Epub 2017 Nov 7
[PubMed PMID: 29113980]
[18]
Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2012 Dec:27(12):2419-28. doi: 10.1002/jbmr.1800. Epub
[PubMed PMID: 23165426]
[19]
Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007 Jun:40(6):1434-46
[PubMed PMID: 17517365]
[20]
Lee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Current opinion in nephrology and hypertension. 2009 Jul:18(4):298-302. doi: 10.1097/MNH.0b013e32832c2264. Epub
[PubMed PMID: 19395963]
Level 3 (low-level) evidence
[21]
Shakeri A, Adanty C. Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique. 2020 Jan 6:27(1):e25-e31. doi: 10.15586/jptcp.v27i1.655. Epub 2020 Jan 6
[PubMed PMID: 31922699]
[22]
Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified tissue international. 2010 Dec:87(6):485-92. doi: 10.1007/s00223-010-9424-6. Epub 2010 Oct 16
[PubMed PMID: 20953593]
[24]
Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates. JBMR plus. 2022 Sep:6(9):e10665. doi: 10.1002/jbm4.10665. Epub 2022 Aug 14
[PubMed PMID: 36111201]
[25]
Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2007 Jan:18(1):59-68
[PubMed PMID: 17013567]
[26]
Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clinical interventions in aging. 2016:11():1653-1659
[PubMed PMID: 27895472]
Level 2 (mid-level) evidence
[28]
Shulman D. Subcutaneous Infusion of rhPTH(1-34) During Pregnancy and Nursing in a Woman With Autosomal Dominant Hypoparathyroidism 1. Journal of the Endocrine Society. 2022 May 1:6(5):bvac031. doi: 10.1210/jendso/bvac031. Epub 2022 Feb 25
[PubMed PMID: 35350394]
[29]
Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society. 2006 May:54(5):782-9
[PubMed PMID: 16696744]
Level 3 (low-level) evidence
[30]
Lucas C, Donovan P. 'Just a repeat' - When drug monitoring is indicated. Australian family physician. 2013 Jan-Feb:42(1-2):18-22
[PubMed PMID: 23529454]
[31]
Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011 Dec:26(12):2823-6. doi: 10.1002/jbmr.530. Epub
[PubMed PMID: 21997141]
[32]
Minisola S, Cipriani C, Grotta GD, Colangelo L, Occhiuto M, Biondi P, Sonato C, Vigna E, Cilli M, Pepe J. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Therapeutic advances in musculoskeletal disease. 2019:11():1759720X19877994. doi: 10.1177/1759720X19877994. Epub 2019 Oct 5
[PubMed PMID: 31632472]
Level 3 (low-level) evidence
[33]
Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2021 Feb:36(2):244-251. doi: 10.1002/jbmr.4188. Epub 2020 Oct 13
[PubMed PMID: 32990990]
[34]
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020 May:26(Suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL. Epub
[PubMed PMID: 32427503]
Level 1 (high-level) evidence
[35]
Kim J, Konkel K, Jones SC, Reyes M, McCulley L. Teriparatide-associated calciphylaxis: a case series. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2022 Feb:33(2):499-504. doi: 10.1007/s00198-021-06139-3. Epub 2021 Sep 8
[PubMed PMID: 34494145]
Level 2 (mid-level) evidence
[36]
Milosavljevic J, Thomas AM. Teriparatide Associated Late Hypercalcemia: A Report of Two Cases and Literature Review. Journal of community hospital internal medicine perspectives. 2022:12(1):54-58. doi: 10.55729/2000-9666.1010. Epub 2022 Jan 31
[PubMed PMID: 35711860]
Level 3 (low-level) evidence
[37]
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (London, England). 2015 Sep 19:386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2
[PubMed PMID: 26144908]
Level 1 (high-level) evidence
[38]
LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2022 Oct:33(10):2049-2102. doi: 10.1007/s00198-021-05900-y. Epub 2022 Apr 28
[PubMed PMID: 35478046]
[39]
Carswell AT, Eastman KG, Casey A, Hammond M, Shepstone L, Payerne E, Toms AP, MacKay JW, Swart AM, Greeves JP, Fraser WD. Teriparatide and stress fracture healing in young adults (RETURN - Research on Efficacy of Teriparatide Use in the Return of recruits to Normal duty): study protocol for a randomised controlled trial. Trials. 2021 Aug 30:22(1):580. doi: 10.1186/s13063-021-05556-3. Epub 2021 Aug 30
[PubMed PMID: 34461961]
Level 1 (high-level) evidence
[40]
Benson CT, Voelker JR. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. Clinical pharmacology and therapeutics. 2003 Jan:73(1):87-94
[PubMed PMID: 12545147]
[41]
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2019 May 1:104(5):1595-1622. doi: 10.1210/jc.2019-00221. Epub
[PubMed PMID: 30907953]
Level 1 (high-level) evidence
[42]
Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicologic pathology. 2002 May-Jun:30(3):312-21
[PubMed PMID: 12051548]
[43]
Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2018 Oct:29(10):2335-2343. doi: 10.1007/s00198-018-4604-8. Epub 2018 Jul 5
[PubMed PMID: 29978254]
[44]
Cantrell L, Farson-Collier M. Clinical Course Following Supratherapeutic Teriparatide Dosing. The Annals of pharmacotherapy. 2011 Feb:45(2):281. doi: 10.1345/aph.1P705. Epub
[PubMed PMID: 21304029]
[45]
Montero-Odasso M, van der Velde N, Martin FC, Petrovic M, Tan MP, Ryg J, Aguilar-Navarro S, Alexander NB, Becker C, Blain H, Bourke R, Cameron ID, Camicioli R, Clemson L, Close J, Delbaere K, Duan L, Duque G, Dyer SM, Freiberger E, Ganz DA, Gómez F, Hausdorff JM, Hogan DB, Hunter SMW, Jauregui JR, Kamkar N, Kenny RA, Lamb SE, Latham NK, Lipsitz LA, Liu-Ambrose T, Logan P, Lord SR, Mallet L, Marsh D, Milisen K, Moctezuma-Gallegos R, Morris ME, Nieuwboer A, Perracini MR, Pieruccini-Faria F, Pighills A, Said C, Sejdic E, Sherrington C, Skelton DA, Dsouza S, Speechley M, Stark S, Todd C, Troen BR, van der Cammen T, Verghese J, Vlaeyen E, Watt JA, Masud T, Task Force on Global Guidelines for Falls in Older Adults. World guidelines for falls prevention and management for older adults: a global initiative. Age and ageing. 2022 Sep 2:51(9):. doi: 10.1093/ageing/afac205. Epub
[PubMed PMID: 36178003]